Infextious Therapeutic is an AJK Biopharmaceutical company founded in 2018. Its mission is combating the life–threatening infectious disease using a novel Cyclic Peptide platform. Its focus is on the clinical development of novel anti-infective therapeutic drugs with emphasis on developing antiviral peptides against SARS-COV2, herpes simplex (HSV), and human papilloma (HPV) viruses, Broad-spectrum antimicrobial peptides with activity against multi-drug resistant bacteria, and Antifungal peptides against Onychomycosis.

​

According to the U.S. Center for Disease Control and Prevention, an increasing number of bacterial have become resistant to currently available antibiotics.

​

According to the CDC's Antibiotic Threat Report, the total estimated financial cost of the antibiotic resistance to the U.S may exceed as high as $20 billion in excess direct healthcare cost and additional social cost for the lost productivity as high as $35 billion a year.